BioStem Technologies (BSEM)
OTHER OTC:BSEM
BSEM Stock Chart & Stats
$4.83
$0.88(5.85%)
At close: 4:00 PM EST
$4.83
$0.88(5.85%)
Day’s Range― - ―
52-Week Range$3.09 - $15.74
Previous CloseN/A
Volume47.30K
Average Volume (3M)59.14K
Market Cap
$84.96M
Enterprise Value$61.28M
Total Cash (Recent Filing)$29.55M
Total Debt (Recent Filing)$3.33M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,338,436
10 Day Avg. Volume75,970
30 Day Avg. Volume59,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue1.29
Enterprise Value/Gross Profit1.39
Enterprise Value/Ebitda-130.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.29
Revenue Forecast (FY)$271.30M
Bulls Say, Bears Say
Bulls Say
Strategic Acquisition & Commercial ExpansionThe BioTissue acquisition immediately expands BioStem into hospital, HOPD and ASC channels and brings an experienced national sales footprint. Adding ~ $29M of historical revenue and re-assigned GPO contracts diversifies payer/customer mix and structurally broadens addressable markets for durable revenue sources.
Clinically Differentiated RCT ResultsStatistically significant DFU RCT results provide a durable clinical advantage that supports hospital adoption and payer coverage. Robust RCT evidence reduces commercialization friction, strengthens formulary/contract arguments, and can sustain higher utilization and pricing power over multiple years as hospitals and payers update protocols.
Manufacturing Margin Upside & Product BreadthA clear plan to in‑source manufacturing within ~12 months targets >80% gross margins versus temporary ~60% outsourced margins. Coupled with expanded product families (Neox, Clarix, CryoTek, SteriTek) and long clinical usage, successful tech transfer materially improves long-term gross margin, cash conversion and scalable profitability.
Bears Say
Revenue Volatility & Sharp DeclineRevenue fell sharply year-over-year and 2025 showed a severe annual contraction, which undermines visibility and earnings quality. Such volatility strains planning for commercialization and manufacturing investments, increases refinancing/dilution risk, and makes multi-quarter margin recovery and cashflow forecasting more uncertain.
Limited Post-Close Cash RunwayPost-acquisition cash of roughly $16M and an expected burn through much of 2026 creates meaningful refinancing risk. Limited runway can force accelerated fundraising or operational cutbacks, potentially diluting shareholders or delaying tech transfer and commercialization steps that are central to margin and revenue recovery.
Reimbursement & Collections Risk (CMS)CMS payment changes and heightened documentation/audit risk create a structural pressure on physician-office channels, and the $8.8M uncollectible allowance highlights tangible collections exposure. Persistent payer uncertainty can depress volumes, delay hospital adoption, and increase working capital needs over several quarters.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies’s price range in the past 12 months?
BioStem Technologies lowest stock price was $3.09 and its highest was $15.74 in the past 12 months.
What is BioStem Technologies’s market cap?
BioStem Technologies’s market cap is $84.96M.
When is BioStem Technologies’s upcoming earnings report date?
BioStem Technologies’s upcoming earnings report date is May 18, 2026 which is in 38 days.
How were BioStem Technologies’s earnings last quarter?
BioStem Technologies released its earnings results on Mar 24, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of $0.02 by -$0.69.
Is BioStem Technologies overvalued?
According to Wall Street analysts BioStem Technologies’s price is currently Overvalued.
Does BioStem Technologies pay dividends?
BioStem Technologies does not currently pay dividends.
What is BioStem Technologies’s EPS estimate?
BioStem Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioStem Technologies have?
BioStem Technologies has 16,338,436 shares outstanding.
What happened to BioStem Technologies’s price movement after its last earnings report?
BioStem Technologies reported an EPS of -$0.67 in its last earnings report, missing expectations of $0.02. Following the earnings report the stock price went down -3.906%.
Which hedge fund is a major shareholder of BioStem Technologies?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
BSEM Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.16%
12-Months-Change
Fundamentals
Return on Equity
-14.25%
Trailing 12-Months
Asset Growth
-64.29%
Trailing 12-Months
Company Description
BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
BSEM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: the call communicated meaningful strategic positives — a transformational acquisition expanding addressable markets, strong clinical data (DFU RCT), product and commercial expansion, and a clear path to materially higher manufacturing margins after tech transfer. However, these longer-term strengths are offset by significant near-term financial headwinds: steep year-over-year revenue declines, a sizable one-time $8.8M allowance tied to distributor collections, higher operating expenses, lower blended margins during a 12-month contract manufacturing period, reduced post-close cash (~$16M) and expected cash consumption through much of 2026. Management has articulated a credible integration and commercialization plan, but near-term liquidity and execution risks temper the outlook.View all BSEM earnings summariesTechnical Analysis
Crescent Biopharma
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Innate Pharma
―